Cancer treatment balances on a razor’s edge. On one side, physicians must use enough of a drug to kill tumor cells effectively. On the other side, a high drug concentration can be harmful to a patient’s normal cells. In children, the difference between the two, called the therapeutic index, is small.  Read more: https://www.stjude.org/research/progress/2025/finding-balance-between-efficacy-and-toxicity-in-pediatric-cancer-treatment.html

A new study led by researchers at the University of Minnesota Medical School has identified genetic factors that may help explain why African American children are less likely to develop acute lymphoblastic leukemia (ALL) but tend to face worse outcomes when they do. Read more: https://twin-cities.umn.edu/news-events/university-minnesota-study-uncovers-new-genetic-factors-childhood-leukemia

The new paper reveals for the first time that these DNA fragments can persist in cancer cells and may drive relapse in patients with...

Chemotherapy resistance is particularly common in what is known as T-ALL, a subtype of ALL. This recent study shows that the origin of...

Planned caesarean births—"C-sections"—slightly raise the risk of some childhood cancers—particularly acute lymphoblastic leukemia (ALL),...

Scientists at St. Jude  Children’s Research Hospital and University Health Network showed that the stage of B-cell development at which...

A combination of two drugs could improve outcomes and reduce the need for toxic chemotherapy for B-cell acute lymphoblastic leukaemia...

New research on children diagnosed with acute lymphoblastic leukemia (ALL) shows that the longer a patient’s body mass index (BMI) falls...

Asparaginase (ASNase) remains a cornerstone of chemo regimens for ALL. But there’s a quiet threat that’s often missed: hypersensitivity...

While the overall prevalence of comorbidities at diagnosis in pediatric patients with acute lymphoblastic leukemia (ALL) and...